1
. Subsequent work established the high molecular weight clostridial toxins toxin A (TcdA) and/or toxin B (TcdB) as the main virulence (disease-causing) factors of C. difficile 2, 3 . A hallmark feature of C. difficile that sets it apart from other species in the class Clostridia is its ability to decarboxylate parahydroxy phenylacetic acid to produce p-cresol, which gives C. difficile its characteristic tar-like or pig-like smell 4 . It was not until the 1970s that a detailed characterization of the bacterium, then called C. difficile, revealed its involvement in human disease 5 . This disease became widely known as C. difficile-associated disease/diarrhoea (CDAD); more recently, the term C. difficile infection (CDI) is preferred. In the early 2000s, an increase in severe cases of CDI was noted in Canada, the United States and Europe 6 , which was attributed to the emergence of certain epidemic types of C. difficile 7, 8 . The first complete genome sequence for C. difficile 9 , together with the development of tools for the genetic manipulation of C. difficile 10, 11 , has greatly stimulated research on the bacterium. C. difficile is now recognized as the leading cause of healthcare-associated infective diarrhoea and is increasingly being linked to community-acquired cases of colitis 12 . C. difficile can be found in the intestinal tracts of both humans and animals, but its spores are also ubiquitous in the environ ment and can be isolated from food 13 . Importantly, people with an adequate immune response will either eliminate the infection and/or become asymptomatic carriers 14 . In 2013, it was proposed that C. difficile should be reclassified as Peptoclostridium difficile on the basis of a detailed phylogenetic analy sis 15 , and this has been adopted by the US National Center for Biotechnology Information. However, considering the public awareness of the disease, the large body of scientific literature using C. difficile and the lack of formal acceptance of this proposal, we will refer to the organism as C. difficile throughout this Primer, and to the disease it causes as CDI. We describe key aspects of the epidemiology of C. difficile infections, the mechanisms underlying the disease, strategies for diagnosis, prevention and management, and summarize the impact that CDIs have on patients and society. disease management. Different types of C. difficile are known; here, we will refer to PCR ribotypes when relevant, a typing system that is based on a banding pattern obtained from PCR amplifying ribosomal 16S-23S intergenic spacer sequences 17 . Certain PCR ribotypes of C. difficile (such as PCR ribotype 010) are nonpathogenic as they lack the toxin genes. Epidemic PCR ribotypes are distinguished from non-epidemic types by their frequent occurrence in multiple settings across several countries.
Owing to a lack of systematic surveillance, no comprehensive data are available on circulating C. difficile types before 2003. After 2003, large increases in incidence and mortality rates in North America -and subsequently in several European countries -were observed, which were associated with PCR ribotype 027 (REF. 8 ) and, to a lesser extent, PCR ribotype 078 (REF. 7 ). Such increases have also been observed in Australia, Asia and Central America after 2008 (REF. 18 ). It should be noted, however, that CDI and CDI-related epidemics are not limited to these types. Ribotypes 001, 002 and 014/020 frequently cause CDI clusters in the United States and Europe 19, 20 . Furthermore, outbreaks have also been reported for strains of other PCR ribotypes, such as 017 (REF. 12) 12 . CDI is historically regarded as a nosocomial infection; antibiotic exposure (either prophylactic or as treatment) during hospitalization is the foremost risk factor for CDI. However, C. difficile is increasingly being recognized as a cause of community-associated diarrhoea. Indeed, PCR ribotypes of strains isolated from patients with community-associated CDI have a large overlap with strains cultured from patients with health-care-associated CDI in an endemic setting, suggest ing a common source (or sources) of C. difficile 24, 25 . The incidence of community-associated CDI is estimated at 30 to 120 cases per 100,000 persons per year in the United States 26 . The incidence of communityassociated CDI in the Netherlands is estimated at 390 to 730 per 100,000 person years, similar to the incidence of Campylobacter spp. infection and higher than the incidence of Salmonella spp. infection 27 . More than 30% of patients who develop community-associated CDI do not have typical risk factors for CDI, such as antibiotic treatment or recent hospitalization (see below) 28, 29 .
The US Centers for Disease Control and Prevention (CDC) estimated that almost 500,000 patients had CDI, with 29,000 attributable deaths in the United States in 2011 (REF. 26 ). However, there is uncertainty regarding the precision of these estimates given the accuracy of the testing methodology, although data have been adjusted based on the frequency of nucleic acid amplifi cation test use. Between 2001 and 2010, the incidence of CDI among hospitalized adults in the United States approximately doubled according to International Classification of Diseases (ICD)-9 discharge diagnoses 30 . Again, ascertain ment bias secondary to awareness (frequency of requesting) and to diagnostic methods could be relevant here.
The first European Centre for Disease Prevention and Control (ECDC) point-prevalence survey in 2011 and 2012 estimated that ~124,000 patients developed health-care-associated CDI within the European Union each year 31 . However, this surveillance was performed with a variety of diagnostic tests, and CDI was often only tested upon physician request, resulting in consider able underestimation of the true CDI incidence; on average, ~80 cases of CDI are missed per hospital per annum in Europe 32 . A pilot study supported by the ECDC using standardized CDI surveillance performed in 37 hospitals in 14 European countries demonstrated large differences in the incidence of CDI per hospital and per country 33 . The incidence of health-care-associated CDI by hospital was in the range of 4.2-131.8 per 10,000 discharges (median 16.4 per 10,000 discharges) and 0.6-18.5 per 10,000 patient days (median 3.7 per 10,000 patient days). In some countries, a high incidence of PCR ribotype 027 strains has been noted, but other countries demonstrated a decrease in the incidence of these strains, most prob ably as a consequence of effective management strategies (see below) 32 . The all-cause mortality associated with CDI due to non-epidemic PCR ribotypes has been reported to be ~15-20% within a month of diagnosis, and approximately half of the deaths are directly attributed to CDI 34 . Given the multiple comorbidities (such as respiratory disease and renal failure) typically present in patients with CDI, mortality is often related to one or more of these conditions. C. difficile is a human pathogen but can also infect and cause disease in animals that can enter the food chain; however, the relevance of foodborne transmission in human disease is unclear 13 . Since the beginning of 2000, C. difficile has been reported as a major cause of neo natal enteritis in piglets. The predominant strains found in piglets (belonging to PCR ribotype 078) are similar to isolates from some human patients with CDI and to isolates from asymptomatic farm workers, suggesting zoonotic transmission 13, 35 . As a consequence of increasing pressure from spores present in the environment and animals, humans might become colonized more frequently. One meta-analysis revealed an increased rate (>8% of admitted patients) of asymptomatic colonization by toxigenic isolates in patients at the time of admission to the hospital 36 . It should be noted, however, that patients who have been admitted to hospital typically have a much higher colonization rate than people in the community, because of exposure to a hospital environment, comorbidities and/or antibiotic use.
Mechanisms/pathophysiology C. difficile lifecycle C. difficile is transmitted via the oral-faecal route (FIG. 2) . Spores are dormant cells that are highly resistant to environ mental conditions 37 , including some disinfectants and many antimicrobials
, which generally target metabolically active cells. Spores are thought to be the infectious vehicle given that vegetative (metabolically active) cells of obligate anaerobic bacteria are unlikely to survive the oxygenated environment outside the host or the acidic environment of the stomach. Indeed, an asporogenic strain of C. difficile is unable to persist in the environment or transmit between hosts 38 . Germination of spores is dependent on sensing primary bile acids from the liver, such as taurocholate, by the germinant receptor CspC and is inhibited by secondary bile acids in the colon 37, 39, 40 . In addition, glycine can act as a germinant through an uncharacterized mechanism 41 . A proteolytic cascade then leads to the degradation of the spore peptidoglycan, release of calcium dipicolinic acid and rehydration of the spore, ultimately resulting in outgrowth of the cells 37, 40 .
The propensity of spores to outgrow and colonize the intestine is greatly influenced by the host microbiota and its associated metabolome 39, 42 . For example, antibiotic-induced shifts in the microbiota can generate an environment conducive to C. difficile infection 43 . Mucolytic enzymes, such as cell surface protein Cwp84 (REF. 44) , are secreted by the bacterium and degrade the colonic mucosa. Bacterial cell surface-associated proteins have been shown to affect the adhesion of the bacterium to colon epithelial cells in vitro [45] [46] [47] [48] ; mutations in genes encoding these proteins, or in the genes encoding proteins for their processing, generally attenuate virulence 49, 50 . The expression of at least a subset of colonization factors by the bacterium, such as cell surface protein Cwp84 and surface layer protein A (SlpA), is stimulated in the presence of the antibiotics ampicillin and clindamycin 51 . Before germination into vegetative cells, spores are also capable of adhering to colon cells 52 . C. difficile is a motile bacterium, and the switch between the sessile and motile phase is regulated by the secondary messenger cyclic di-GMP [53] [54] [55] . C. difficile is also capable -at least in vitro -of forming robust biofilms [56] [57] [58] . Cellcell signalling contributes to both colonization and virulence factor expression 59, 60 . Host recognition of C. difficile is mediated via pattern recognition receptors and myeloid differentiation primary response 88 (MYD88)-and nucleotide-binding oligomerization domain-containing protein 1 (NOD1)-dependent pathways 61, 62 (FIG. 3) . Specifically, SlpA can activate a Toll-like receptor 4 (TLR4)-dependent response 63 , flagellin can stimulate TLR5 (REF. 64 ) and NOD1 is probably activated via peptidoglycan-derived compounds 65 . The first line of host defence against C. difficile is the production of antimicrobial compounds such as lysozyme and cationic antimicrobial peptides 66, 67 . Interestingly, the bactericidal α-defensins, but not β-defensin 1 or cathelicidin anti microbial peptide (also known as LL-37), can also inhibit the activity of the TcdB (see below) through a mechanism that involves direct binding to the toxin 66 . Innate lymphoid cells, specifically class 1, are implicated in resistance against CDI 68 .
Resistance of the bacterium to host-produced antimicrobial compounds is multifactorial 69 and mediated by, for example, the extracytoplasmic function (ECF) sigma factor CsfV 70 , the site-1 protease PrsW 71 , the proteins encoded by the cpr locus 72 and modulation of cell wall charge 73 .
The large clostridial toxins TcdA and TcdB
Regulation of expression. Although several virulence factors contribute to the retention of C. difficile within the gastrointestinal tract 74, 75 , the symptoms of CDI corre late with the presence of a toxin-encoding pathogenicity locus (PaLoc) in the bacterial genome 76, 77 . In most strains, the PaLoc is located at the same site in the chromosome 77, 78 . The PaLoc in most pathogenic C. difficile strains encodes two large homologous toxins (TcdA and TcdB) and three proteins that seem to regulate toxin production and secretion (TcdR, TcdE and TcdC) 74, 75, 78 (FIG. 4a) . TcdR is a member of the ECF family of alternative sigma factors and is critical for the initiation of TcdA and TcdB production in C. difficile 79, 80 . TcdC is thought to encode an anti-sigma factor that negatively regulates toxin production 81 . Epidemic ribotype 027 strains carry a nonsense mutation within the tcdC gene, leading to the suggestion that derepression of the toxin genes by the inactivation of TcdC might contribute to the increased virulence of these strains 82 . However, despite many studies aimed at defining the role of TcdC in toxin production and virulence, conflicting findings have been reported and the functional role of this protein remains unclear 75 . TcdE has homology with bacteriophage holin proteins, which are involved in the release of progeny phages from infected bacterial cells 83 . The role of TcdE is also poorly understood, although some evidence suggests that it facilitates toxin (TcdA and TcdB) secretion 78, 84, 85 . TcdA and TcdB do not possess any recognizable signal or export sequences, suggesting that they might be exported from the bacterial cell by lysis or a non-classic secretion pathway, possibly involving TcdE 84, 85 . The synthesis of TcdR and the subsequent activation of tcdA and tcdB expression is influenced by many environmental stimuli, including short-chain fatty acids such as butyric acid that are common in the gut and sub-inhibitory concentrations of certain anti microbials that may be relevant in the context of disease 79, [86] [87] [88] [89] . Amino acids such as proline, cysteine and certain branched chain amino acids in the local environ ment of the bacterium repress toxin production through the action of the global transcriptional regulator CodY (known as GTP-sensing transcriptional pleiotropic repressor CodY) 90 . The presence of glucose or other rapidly metabolizable carbon sources in the local environ ment of the bacterium also inhibits the production of TcdA and TcdB via the carbon catabo lite control protein A (CcpA) 91, 92 . The sigma factor SigD, which is associated with the expression of motility genes, promotes toxin gene expression by binding to a SigDdependent promoter sequence upstream of tcdR 93, 94 . The master regulator of sporulation in both Bacillus and Clostridium species, Spo0A, can also regulate toxin production in C. difficile, but only in some strains 95 . Specifically, Spo0A negatively regulates TcdA and TcdB production in epidemic type PCR ribotype 027 strains but not in others that have been tested [95] [96] [97] . These results highlight the heterogeneous nature of C. difficile isolates and the need to study strains belonging to distinct evolutionary lineages 95, 98 . Finally, growth signals and cell density play an important part in toxin regulation 59, 60 . Cell-cell signalling is partially dependent on an accessory gene regulator quorum signalling system, which is mediated by a novel thiolactone quorum signalling peptide 59, 60 . Overall, C. difficile toxin synthesis is closely connected to the metabolic state of the bacterium and its environment 99 .
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Mechanism of action.
Structural and functional studies have provided insight into the mechanisms of action of all of the C. difficile toxins, particularly TcdA and TcdB. Once secreted, TcdA and TcdB bind and enter the colonic epithelium to cause inflammatory chemokine and cytokine production, an influx of neutrophils, disruption of tight junctions, fluid secretion and epithelial cell death 100 (FIGS 5, 6) . Given the homology between the two proteins, it is notable that TcdA and TcdB have markedly different functions in animal toxicity models. Historically, TcdA has been viewed as the more potent enterotoxin, as administration of purified TcdA into the intestines of rabbits and rodents causes tissue necrosis and an intense infiltration of immune cells [101] [102] [103] . High levels of TcdB in identical experiments failed to induce these effects, although it should be noted that most of these studies were conducted in an ileal loop model and, accordingly, represent only the response 248 . In addition, sequence-based methods, such as multilocus sequence typing (MLST) and whole-genome sequencing (WGS; specifically single-nucleotide polymorphism (SNP) typing), have gained interest specifically to study evolutionary relationships between various C. difficile strains (phylogeny) 17 . Overall, different lineages can be discriminated and several different PCR ribotypes have been shown to be closely related to the epidemic types using these sequence-based methods 98, 230 . WGS is also used to study transmission and outbreaks 25, 231 , although this approach can be costly and is predominantly performed retrospectively. Relatedness of strains in an outbreak setting is more commonly performed using multilocus variable-number tandem repeat analysis 17 . of the small intestine. In studies involving human colonic tissue, TcdB seems to be a potent inflammatory toxin 104, 105 , whereas TcdA is weaker 104 . These data suggest that the differential toxin responses might partially stem from differences in receptor tropism and highlight the importance of conducting mechanistic studies within the colon, which is the site of bacterial outgrowth in the host.
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TcdA and TcdB have four functional domains 100, 106 : an amino-terminal glucosyltransferase domain (GTD), an autoprotease domain (APD), a pore-forming and delivery domain, and the combined repetitive oligopeptides (CROPS) domain, which extends from around residue 1,830 to the carboxyl terminus (FIG. 5a,b) . A combination of electron microscopy and X-ray crystallography studies has revealed the structural organization of these domains in TcdA and suggests that the structure of TcdB is similar 106, 107 . TcdA and TcdB enter cells via receptor-mediated endocytosis 108 . Historically, receptor binding has been associated with a CROPS domain located at the C termini of TcdA and TcdB 109 . The CROPS domain is capable of binding carbo hydrates, which is consistent with the model wherein TcdA engages glycosylated receptors 110 . Evidence support ing the idea that the TcdA CROPS domain contributes to receptor binding includes the observations that antibodies against the TcdA CROPS domain can block intoxication 111 and that excess TcdA CROPS domain can compete with TcdA holotoxin for cell binding 112 . TcdA binds a variety of carbohydrates, and although multiple glycolipids and glycosylated proteins have been proposed as receptors 109 , the specific receptors used to bind human epithelial cells remain unknown. However, accumulating evidence suggests that domains other than CROPS participate in receptor binding. Indeed, TcdA and TcdB lacking CROPS domains are still capable of intoxicating cells 113, 114 , and the homologous toxin TpeL from Clostridium perfringens lacks a CROPS domain entirely 115 . Recently, two protein receptors have been reported for TcdB: poliovirus receptor-like protein 3 (PVRL3; also called nectin 3) 116 and chondroitin sulfate proteoglycan 4 (CSPG4) 117 . PVRL3 is highly expressed on the surface of human colon epithelial cells and co-localizes with TcdB in tissue resected from a C. difficile-infected individual 116 , suggesting that PVRL3 could serve as the initial receptor that TcdB encounters in the context of infection. CSPG4 is highly expressed in the intestinal subepithelial myofibroblasts of mouse and human intestines 118 , suggesting that this receptor could be engaged after initial damage to the colonic epithelium 117 . Both CSPG4 and PVRL3 bind outside the CROPS domain 116, 117 . It is conceivable that additional alternative receptors for TcdB exist.
Following receptor binding and endocytosis, acidification of the endosome is thought to trigger a structural change in the delivery domain, facilitating pore formation and translocation of the GTD into the cytosol 109 (FIG. 5c). The APDs share sequence homology with the cysteine protease of the MARTX family of toxins 119, 120 , but one publication has shown that the catalytic dyad of TcdA and TcdB serves to coordinate a zinc ion that is essential for function 106 . Activation of the APD by eukaryotic inositol hexakisphosphate (InsP 6 ) results in the release of the GTD into the cell, enabling access to cytosolic substrates 119, 120 . Host S-nitrosylation at the conserved cysteine of the APD can inactivate the protease activity in an InsP 6 -dependent manner 121 . It has been hypothesized that the autoprotease and translocation efficiency of the epidemic PCR ribotype 027 strain contribute to its increased virulence 122 . The GTD transfers glucose from UDP glucose onto RHO family GTPases such as RHO, RAC1 and cell division A range of host factors influence the Clostridium difficile life cycle, as well as the relative numbers of spores and vegetative (metabolically active) cells in the gut. Note that passage through the stomach eliminates most vegetative cells (but spores survive), and spores germinate and grow out in the duodenum. In the caecum and colon, C. difficile starts producing spores again, and vegetative cells are excreted by the patient during infection. Toxin is produced in the colon. As C. difficile is an obligate anaerobic bacterium, transmission occurs primarily via spores. SCFA, short-chain fatty acid (such as butyrate).
control protein 42 (CDC42) 123, 124 . These modifications cause a cytopathic effect resulting from rearrangement of the actin cytoskeleton and can lead to apoptosis 125 (FIG. 5c). At higher concentrations, TcdB is also capable of coordin ating the assembly of the NADPH oxidase complex on endosomes 126 . The resulting production of reactive oxygen species leads to cell death by a necrotic mechanism 126 (FIG. 5d) . Both mechanisms might be important in the context of disease; cytopathic effects promote inflammation and disruption of the tight junctions, whereas TcdB-induced necrosis contributes to the colonic tissue damage observed in severe cases of CDI.
Knowledge of the mechanisms of action of C. difficile toxins has served as a foundation for several preclinical studies aimed at identifying small-molecule inhibitors of intoxication, particularly those that are already approved for other uses 127 . A recent screen for inhibitors of TcdBinduced cytopathic effects identified compounds that act by inhibiting toxin binding to cells, endosomal maturation or glucosyltransferase function 128 . Another screen, conducted using an activity-based probe for inhibitors of the APD, identified ebselen, a FDA-approved compound, which reduced tissue pathology in a mouse infection model 129 . Notably, ebselen has also been reported to block NADPH oxidase 1 activity 130 , a function that could contribute to a decrease in toxin-induced production of reactive oxygen species. Similarly, N-acetylcysteine, an FDA-approved antioxidant, prevented TcdB-induced tissue damage in a colonic explant model 126 .
Pathology. Although the roles of TcdA and TcdB in the context of CDI have been difficult to assess, recent progress has come through advances in the genetic manipulation of C. difficile. Four studies have been conducted in both hamster and mouse models of infection. All studies indicate that TcdB is capable of inducing the phenotypes of disease in the absence of TcdA, but differ on the interpretation of the role of TcdA in the absence of TcdB on the survival of animals 2, 3, 131, 132 . Histological examin ation of colonic and caecal tissue from mice infected with TcdB-positive C. difficile strains (either wild-type TcdA + TcdB + or TcdA − TcdB + mutants) showed severe gut damage associated with eroded and often absent crypts, mucosal ulceration and goblet cell loss 132 . Polymorphonuclear cell influx into the lamina propria, enterocyte hyperplasia and severe submucosal oedema associated with haemorrhage were also observed in these tissues. TcdB-negative strains (TcdA + TcdB − ) caused less tissue damage that was confined to mild oedema and polymorpho nuclear cell influx 132 . Tissue damage was strictly dependent on TcdB or TcdA given that tissues from mice infected with a strain that did not produce TcdA or TcdB (TcdA − TcdB − ) resembled those of mock-infected control animals 132 
(FIG. 6).
Consistent with the finding that TcdB is independently capable of causing disease, a considerable number of clinical C. difficile isolates express only TcdB 133 . The prevalence of these strains, which include PCR ribotype 017, has been increasing, sometimes to epidemic proportions 134 . Recently, the first strain with an intact tcdA gene, but no tcdB gene, in a different genomic context than the PaLoc has been characterized 78 . This work has raised the hypothesis that the single toxinencoding loci might have fused to form the typical twotoxin locus (PaLoc), which is the most common form currently detected in clinical isolates. The study also suggests a conserved relation ship between the presence of toxin genes and holin genes, and demonstrates that the PaLoc does not always encode a tcdC homologue 78 . However, it should be noted that confirmed clinical cases of CDI caused by strains that only produce TcdA are extremely limited 78 .
Binary toxin CDT
Regulation of expression. C. difficile transferase (CDT; or binary toxin) is a third toxin produced by some C. difficile strains, including the epidemic PCR ribotypes 027 and 078. CDT has received increased attention in recent years because of its increasing prevalence in isolates of both human and animal origin 135 . CDT is encoded by two genes, cdtA and cdtB, that are located in an operon on the binary toxin locus (CdtLoc) 136, 137 (FIG. 3b) . In CDTnegative strains, this locus contains an ~2 kb deletion 138 . The CdtLoc also harbours a response regulator gene, cdtR, upstream of the cdtAB operon 139 . CdtR is an orphan LytTR-like positive transcriptional regulator of the cdt operon and CDT production. The cognate sensor histidine kinase that interacts with the orphan histidine kinase CdtR has yet to be identified 139 . A truncation in the C. difficile PCR ribotype 078 CdtR does not abrogate CDT expression, suggesting that full-length CdtR is not essential for expression 140 . In contrast to the PaLoc, the environmental signals that regulate the expression of the CdtLoc genes are not known.
Box 2 | Antibiotic resistance of Clostridium difficile
Most antimicrobial compounds target metabolically active cells and have limited or no activity against dormant cells, such as spores. This intrinsic resistance of spores ensures that Clostridium difficile can persist in the presence of antibiotics or in the host immune system 249, 250 . C. difficile also demonstrates extensive acquired antimicrobial resistance 9, 251 . Interestingly, C. difficile vegetative cells are sensitive to teicoplanin and vancomycin despite harbouring a genomic region that resembles a vanG glycopeptide resistance cluster 9, 252 . This cluster can confer vancomycin resistance to a heterologous host, but why it is not functional in C. difficile is unclear 253 . The mobile genome of C. difficile (which consists of transposons, insertion sequences and (pro) phages) probably contributes to antibiotic resistance because these elements commonly contain resistance determinants 9, 254 . For example, the Tn6218 element of C. difficile contains a cfr-like gene that can confer resistance to peptidyl transferase inhibitors such as linezolid 255 and the Tn5397 element carries a tetracycline resistance determinant 256 . Reduced susceptibility or resistance to the commonly used antibiotics vancomycin, metronidazole and fidaxomicin has been noted [257] [258] [259] [260] . Although this is cause for concern, the clinical relevance of resistance to these antibiotics so far is limited. However, C. difficile antibiotic resistance is only part of the reason why C. difficile has been classified as an Urgent Antibiotic Resistance Threat by the US Centers for Disease Control and Prevention 261 . Other major factors include the bacterium affecting people treated by antibiotics for other infections, the ageing of the general population and the emergence of epidemic types, such as PCR ribotype 027. At least in this ribotype, epidemic lineages are associated with resistance against fluoroquinolones 8 ; although this class of antibiotics is not used for the treatment of C. difficile infections, the antibiotics can select for C. difficile when used to treat other infections. Fluoroquinolone resistance is also common in other PCR ribotypes 262 .
Mechanism of action.
Recent studies have provided insight into the mechanisms of action of CDT, although the role of this toxin in disease pathogenesis remains unclear. CDT belongs to the binary ADP-ribosylating toxin family and consists of two components: an enzymatic component (CDTa) and a binding/translocation component (CDTb). CDTa has ADP ribosyl transferase activity, whereas CDTb facilitates the passage of the enzymatic component to the cell cytosol 135 (FIG. 7) .
CDTa leads to the complete destruction of the actin cytoskeleton and, ultimately, cell death 135, 141 .
Pathology. Despite a thorough understanding of the mechanism of action of CDT on intoxicated cells, the role of this toxin in disease pathogenesis is unclear. Experimental data have suggested that CDT results in the formation of microtubule-based protrusions on epithelial cells that might increase the adherence and colonization of C. difficile 142 . Importantly, the increasing presence of CDT in clinically relevant strain types commonly associated with severe CDI, such as PCR ribotypes 027 and 078, and the isolation of TcdA − TcdB − CDT + strains suggest that this toxin is likely to play an important but as yet undefined part in CDI 143, 144 .
Experimental models
Multiple experimental models have been developed as a proxy for CDI and its treatment in humans [145] [146] [147] . The most common models are the female golden (Syrian) hamster model, which is exquisitely sensitive to toxin and is primarily suited to study acute disease, and the mouse model. The mouse model mimics certain aspects of human disease that are difficult to assess in hamsters; for instance, mice can be colonized asymptomatically, they exhibit differential sensitivity towards different PCR ribotypes and they can experience relapsing disease. For these reasons, the model is suitable to study colonization, transmission and persistence phenotypes 38, 148, 149 . A piglet model is of particular interest to study C. difficile strains that are problematic in both animal and human populations 13, 35, 150 . In vitro gut models have been developed to study interactions of C. difficile with therapeutics in the context of a complex microbiome 13, 151, 152 . Each model is greatly influenced by variables such as qualitative and quantitative differences in inoculum and the choice of C. difficile strain 147 . Furthermore, non-animal models (for example, the in vitro gut models) may not fully reflect the interaction with the host, but some have been shown to be more reflective of human CDI than animal models 147 .
Diagnosis, screening and prevention
Symptoms and risk factors
The clinical symptoms associated with CDI range from mild, self-limiting diarrhoea to fulminant colitis, and can include pseudomembranous colitis (FIG. 1d) , toxic megacolon (severe dilatation of the colon), bowel perforation and sepsis, and/or multiple organ dysfunction syndrome 14, 132, 153 . Given that the characteristics (for example, age, use of medication or underlying comorbidities) of patients who can acquire CDI are highly variable, there is considerable variation in the possible severity assessments for this disease, which is reflected in the differing criteria used in guidelines 154, 155 . Severe diarrhoea associated with C. difficile Nature Reviews | Disease Primers is often accompanied by a typical endoscopic picture of pseudo membranous colitis with haemorrhage and deep ulcerations. Toxic megacolon is considered the most serious disease entity and is characterized by systemic toxicity and high mortality. Extra-intestinal manifestations of CDI (including bacteraemia) are extremely rare, and this emphasizes that it is the localized effects of toxins, associated with depleted intestinal micro biota, that cause the range of signs and symptoms of CDI. C. difficile toxins in sera from patients with CDI can be detected with an ultra sensitive cell-based assay 156 , but studies are required to assess the relationship between severe CDI and levels of toxaemia.
Known risk factors for CDI are previous hospitalization, underlying disease, advanced age (>65 years) and, most importantly, the use of antibiotics. All antibiotic classes can be associated with CDI, but clindamycin, cephalosporins and fluoroquinolones are the most frequently cited 157 . Antibiotic-induced dysbiosis of the protective intestinal microbiota often underlies C. difficile outgrowth and toxin production 39, 43 . Thus, even low-risk antibiotics (such as trimethoprim and piperacillin-tazobactam) can predispose the patient to CDI, especially when two or more courses of (different) antibiotics are prescribed; the cumulative damage to the intestinal microbiota could be sufficient to enable C. difficile to proliferate.
In addition to the antibiotic class, the number of administered antibiotics, dose and duration of therapy have been identified as risk factors for CDI. Given that disruption of the intestinal flora persists for >3 months after antibiotic therapy, patients can remain susceptible to CDI development long after ending the treatment 28 . Acid suppression by proton pump inhibitors (commonly used for dyspepsia, peptic ulcer disease and gastroesophageal reflux disease) has frequently been associated with CDI 158,159 but the precise role of proton pump inhibitors in CDI (and a causal relation ship) remains unclear 160, 161 . Of all patients with antibiotic-associated diarrhoea, 20-30% is caused by C. difficile 162 . A differential diagnosis could consider a role for Staphylococcus aureus, C. perfringens, Clostridium sordellii or Klebsiella oxytoca as causative agents of antibiotic-associated diarrhoea 163 .
Diagnosis
The mainstay for diagnosing CDI is the presence of clinical symptoms plus a well-chosen laboratory assay. The diagnostic tests for C. difficile can be divided into tests for C. difficile products (glutamate dehydrogenase (GDH), aromatic fatty acids, TcdA and/or TcdB); culture methods for the detection of toxin-producing C. difficile (toxigenic culture); and nucleic acid amplification tests for C. difficile genes (detecting 16S rRNA, toxin genes or the gene encoding GDH) 162 . The test selection is important to differentiate between patients with CDI and asymptomatic carriers 34, 164 . Tests that detect toxins are specific to CDI, whereas those that detect (a component of) the bacterium might indicate colonization rather than disease 34, 164 . Exclusive reliance on molecular tests for CDI diagnosis without tests for toxins is likely to result in overdiagnosis and overtreatment 34, 165 . Owing to large variations in sensitivity and specificity of various diagnostic tests, the European Society of Clinical Microbiology and Infectious Diseases recommends using a two-step algorithm, including a test for the presence of C. difficile and one to detect free toxins in the faeces 166 . As tests remain positive for toxins during treatment and toxins can even be found after successful treatment 167 , regular monitoring using toxin tests as follow up for treatment is not advised. If free toxins are absent, CDI is highly unlikely (FIG. 8) . Importantly, C. difficile toxin assays vary markedly in their sensitivity 34, 164, 168 . If C. difficile is present but the toxin test result is negative, CDI cannot be definitively excluded. Patients could be (asymptomatically) colonized by C. difficile with diarrhoea due to an alternative cause or could be experiencing CDI with toxin levels below the lower limit of detection of the assay used. For these patients, clinical evaluation is required to decide whether treatment for CDI is warranted.
An alternative diagnostic algorithm uses a coupled enzyme immune assay that simultaneously detects both GDH and TcdA or TcdB 169 . As the sensitivity of the toxin component is unclear, samples that are GDH-positive but toxin-negative could undergo reflex testing using a nucleic acid amplification test to determine whether a toxigenic C. difficile strain is present. Ideally, every laboratory should also have the opportunity to isolate C. difficile from faecal samples. Isolation enables toxigenic culture and susceptibility testing, and offers the ability to perform molecular typing that is required for surveillance 
Screening
There is considerable variation between and within countries in the diagnostic algorithm applied but also the frequency of testing (when to test). A study involving ~500 hospitals in 20 countries across Europe revealed that 23% of diarrhoeal samples with a positive CDI test result (at a reference laboratory) were initially missed owing to a lack of clinical suspicion 32 . Hence, restricting the testing of samples to those for which a physician has requested CDI testing will lead to underdiagnosis. All stool samples from hospitalized patients with diarrhoea should be tested unless a plausible Figure 5 | Structure and function of the large clostridial toxins. a | Schematic of the toxin A (TcdA) and TcdB primary structures, highlighting the four functional domains: the glucosyltransferase domain (GTD; red), the autoprotease domain (APD; blue), the delivery domain (yellow) and the combined repetitive oligopeptides (CROPS) domain (green) that binds carbohydrates on the host cell surface to facilitate bacterial entry. b | Overlay of an electron microscopy reconstruction of the structure of TcdA with the X-ray crystal structure of TcdA lacking the CROPS domain (Protein Data Bank code: 4R04). Colour-coding reflects the domain structure in part a. c | The discrete structural and functional domains of the toxins contribute to a multi-step mechanism of intoxication. Toxins bind to one or more receptors (carbohydrate and/or protein) on the cell surface (step 1) and are internalized by receptor-mediated endocytosis (step 2). As the endosome matures, the V-ATPase contributes to a decrease in pH (step 3). The acidic pH causes a conformational change in the toxin delivery domain, resulting in pore formation (step 4) and the translocation of the APD and GTD into the cytosol (step 5). Inositol hexakisphosphate (InsP 6 ) binds and activates the APD, resulting in the release of the GTD (step 6), which can inactivate RHO family proteins (step 7) to cause apoptosis and cytopathic 'rounding' effects. d | At concentrations >0.1 nM, TcdB can promote RAS-related C3 botulinum toxin substrate 1 (RAC1) activation (step 1) and complex formation between p22phox (also known as cytochrome b-245 light chain), NADPH oxidase 1 (NOX1), NADPH oxidase activator 1 (NOXA1), NADPH oxidase organizer 1 (NOXO1) and RAC1 on the endosomal membrane to form the NOX complex (step 2). The fully assembled NOX complex generates superoxide by transferring an electron from NADPH to molecular oxygen (step 3). Superoxide generation leads to the production of reactive oxygen species (ROS), which -at high levels -promote necrosis by causing mitochondrial damage, lipid peroxidation and protein oxidation (step 5). alternative explanation (such as laxative use or diagnosis of inflammatory bowel disease) is available 155, 164, 170 or if the patient is <2 years of age. Indeed, C. difficile is commonly found in the faeces of healthy infants, and there is no general agreement on how to define CDI in children or when to test for CDI in children, especially with respect to age, underlying disease and use of antibiotics 1, 171 . However, CDI can occasionally occur in infants and young children, and can cause microscopic intestinal lesions with symptoms other than diarrhoea. The American Academy of Pediatrics has recently recom mended testing for CDI only if age-specific clinical criteria are met 172 . As C. difficile is increasingly recognized as a causative agent of community-associated diarrhoea, one can consider testing all diarrhoeal samples from community patients, although it can be cost-prohibitive to test a large number of samples. Application of specific algor ithms, such as testing those with diarrhoea who have previously been hospitalized or used antibiotics, results in recognition of only 61% of patients with CDI in the community 28 . The introduction of multiplex molecular tests for enteric pathogens makes it easier to implement routine testing (screening) for CDI, although positive tests of C. difficile should be followed by a stool toxin detection test (two-step algorithm). In a European, multi centre, quarterly point-prevalence study of communityacquired diarrhoea using molecular tests, C. difficile was found among 709 samples to be the third most frequently occurring pathogen, after enteropathogenic Escherichia coli and Campylobacter spp. 173 . In that study, children were also included (potentially identifying colonized rather than infected individuals) and a large variation per country was observed 173 . C. difficile occurred more frequently in the >60-year age group than in other age groups. Application of molecular diagnostics in a case-control study of patients with diarrhoea attending a general practitioner in the Netherlands revealed that C. difficile was present in 4.2% of 1,515 cases and 0.8% of 1,195 healthy controls 174 . This number is considerably higher than the prevalence of Salmonella spp. and Shigella spp., and confirmed that C. difficile is frequently found in general practice 24 .
Asymptomatic carriage
For both health-care-and community-associated infection, it is necessary to differentiate between colonization and disease 34, 164, 165 . Carriage and colonization are often deemed to be interchangeable terms 175, 176 . Indeed, the criteria used to determine asymptomatic carriage and/or colonization vary markedly between studies. A clarification of terminology is required, as a single C. difficile-positive faecal sample could indicate colonization, transient carriage or 'pass through' (REF. 177 ). We prefer to use the term 'carriage' to refer to persistent colonization.
Most studies use just one single culture and, therefore, evaluate passage or transient colonization, defined here as asymptomatic colonization. Asymptomatic C. difficile colonization is common in health-care facilities and in the community, and can be attributable to toxin-positive or toxin-negative strains 36, [178] [179] [180] . In hospitals, the prevalence of asymptomatic colonization varies from 7% to 18%, depending on the length of stay, exposure to antibiotics and to C. difficile (infection pressure), underlying disease and possibly use of acid-suppressive medication. Indeed, the environment is most contaminated in rooms of patients with CDI, less so in rooms of patients asymptomatically colonized with C. difficile and least in patients who are not colonized 181 . During outbreaks, colonization rates may further increase to >50% 179 . Asymptomatic colonization in the community is lower than in the health-care setting and is in the range of 2-4%. Several studies report high carriage rates (25-35%) in children in the first year; the rate drops (to 15%) for ages 1-8 years [182] [183] [184] . This variation is probably associated with the unstable intestinal microbiota in the first 2-3 years of life, which enables C. difficile to remain established in the intestinal tract 185 . Interestingly, high levels of free toxin can also be detected in faecal samples of young children without diarrhoeal symptoms, therefore, further reinforc ing the need for information on the effects of toxins on intestinal epithelial cells in children.
Asymptomatic colonization has been considered a protective factor against the acquisition of new C. difficile isolates. A frequently cited meta-analysis of four studies from 1994 showed that patients colonized with C. difficile actually had a lower risk of subsequently developing CDI, but no distinction was made between colonization by toxigenic versus non-toxigenic strains 186 . A recent meta-analysis included studies in which patients were colonized with toxigenic strains at hospital admission only 36 . It should be noted that in this study, unlike the previous study 186 , patients with previous CDI were not excluded and this could have confounded the results. Overall, the patients who were colonized had an increased risk of developing CDI (relative risk 5.86; 95% confidence interval 4.21-8.16). By contrast, patients asymptomatically colonized by non-toxigenic strains do not seem to have an increased risk or are even protected from progressing to CDI. This concept was recently tested in humans; patients who could be colonized by a non-toxigenic C. difficile strain after receiving standard of care treatment for CDI had significantly reduced CDI recurrence rates 187 . However, further explorations of this approach should consider that non-toxinogenic strains can become toxinogenic by horizontal gene transfer 188 , although it is unknown whether this process also occurs in a human host.
Asymptomatically colonized patients can shed spores into their environment and consequently to other patients. As early as 1992, it was recognized that nosocomial acquisition of a C. difficile strain was preceded by introduction of that strain to the ward by an asymptomatically colonized patient 189 . On the basis of an epidemiological model of C. difficile transmission in health-care settings, admission of colonized patients was shown to play an important part in sustaining wardbased transmission 190 . This observation needs confirmation as it could have major implications for infection control and prevention measures.
Management
Infection control
Several reviews and guidelines for controlling CDI have been published 154, 155, 157, [191] [192] [193] [194] [195] . Although some differences exist, most of these guidelines have similar recommendations
. If a patient is suspected of having CDI, rapid diagnostic testing should be performed to enable treatment initiation as soon as possible. Spores are highly infectious and problematic in health-care settings as they are able to persist on surfaces and are resistant to many disinfectants and alcohol-based hand washes 37 . Up to 1 × 10 7 spores per gram of faeces are present in patients with CDI, representing considerable potential for environmental contamination. Consequently, treatment should always be combined with patient isolation to prevent spread of C. difficile or other enteropathogenic microorganisms.
In a health-care setting, transmission of C. difficile spores occurs primarily via the contaminated hands of health-care workers, but contact with a contaminated environment, contaminated utensils or medical devices has also been implicated; C. difficile spores have been identified in rooms of patients who have tested negative. Environmental decontamination of clinical areas, ideally using chlorine-releasing agents or a sporicidal product, is recommended; however, in practice, compliance with cleaning protocols is often suboptimal 154 . Newer alternatives for environmental decontamination have been introduced, notably gaseous hydrogen peroxide and, more recently, UV decontamination 196 . The former is particular effective at killing C. difficile spores, but the cost-effectiveness of these approaches is unclear.
Antimicrobial therapy and surgery
The currently available antibiotics that are recommended for treatment of CDI are metronidazole, vancomycin and fidaxomicin (FIG. 8) . Stopping the inciting antibiotics and clinical observation can treat very mild CDI that has been induced by antibiotics 155 . Patients with mild-to-moderate CDI can be treated with oral metronidazole whereas oral vancomycin is recommended for severe or complicated infections 154, 155, 193 . Two multinational randomized controlled trials included patients managed with either vancomycin or metronidazole 197 . Metronidazole was inferior to vancomycin on an intentto-treat basis (clinical cure rates 72.7% versus 81.1%). Also, in a post-hoc multivariate analysis, vancomycin, treatment-naive status and mild-to-moderate CDI severity predicted treatment success.
Concomitant antibiotics are associated with reduced clinical cure, increased recurrence rates and longer time to cessation of diarrhoea 198 . Consequently, additional measures to curb CDI include discontinuation of unnecessary antimicrobial therapy (that is, Clostridium difficile transferase (CDT) is a binary toxin consisting of the CDTa ADPribosyltransferase (red) and the CDTb protein (yellow and green). The monomeric form of CDTb binds to the lipolysis-stimulated lipoprotein receptor (LSR) 263 , which is found in many tissues, including the gut. CDTb undergoes proteolytic activation and oligomerizes to form a heptameric prepore, which facilitates the binding of CDTa to the prepore-receptor complex. This complex enters cells by endocytosis and as the endosome matures, the V-ATPase contributes to a decrease in pH. The low pH of the endosome triggers pore formation and the translocation of CDTa into the cell. Once in the cytosol CDTa, ribosylates actin at arginine 177, resulting in a dual effect whereby G-actin polymerization is inhibited and F-actin depolymerization is favoured, which leads to the complete destruction of the actin cytoskeleton and, ultimately, cell death 135, 141 . Inset, structure of CTDa (Protein Data Bank code: 2WN7).
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CDTa CDTb for the presenting infection), as well as avoidance of anti-motility medications and reviewing proton pump inhibitor use 155 . Patients with complicated CDI with ileus (paralysed bowel) or toxic megacolon, in whom oral antibiotics cannot reach the disease site, can be treated with vancomycin delivered per rectum plus intravenous metronidazole.
Fulminant CDI is a highly lethal disease with mortality rates of up to 80%. These patients often require a total abdominal colectomy, but there is no established management protocol. Alternatively, a diverting loop ileostomy and colonic lavage might be associated with reduced morbidity and mortality 199 . Surgical therapy should be considered in patients with toxic megacolon, clinical signs of sepsis and severe organ dysfunction, acute abdomen and severe ileus. A white blood cell count of ≥15,000-20,000 per μl and elevated serum lactate (>5.0 mM) might serve as markers of disease severity 154, 155, 200 .
Recurrent infection
After treatment of an initial episode of CDI, the chance of a recurrence within 8 weeks is 15-25%; for a patient with 1-2 previous recurrences, the risk of further recurrences is 40-65% 201 . Recurrences are associated with an impaired immune response to C. difficile toxins and/or alteration of the colonic microbiota. Fewer recurrences occur after treatment with oral fidaxomicin (13%) than with vancomycin (25%) 202, 203 . However, after a first recurrence, optimal treatment options are less clear, but fidaxomicin might be effective 198, 202, 203 . Despite these shortcomings, fidaxomicin is generally used for treating a first recurrence of CDI, unless disease has progressed from non-severe to severe (FIG. 8) . Given that the main strength of fidaxomicin is prevention of recurrent infections (except for those due to PCR ribotype 027 that generally respond less well to antibiotics), clinical prediction markers for recognizing patients at risk for recurrent CDI could be helpful. Multiple risk factors for recurrent CDI have been suggested in the literature, but as not all of these are evident at the time of treatment initiation, it is difficult to select appropriate parameters. Age >65 years, concomitant antibiotics, renal failure, history of previous CDI, possibly continued use of antacid medications and initial disease severity 155, 204 are associated with increased risk of recurrence.
Bacteriotherapy and faecal transplantation
Limited evidence supports the use of probiotics to decrease recurrence of CDI, and no effective immunotherapy is currently available 205 . Faecal micro biota transplantation (FMT) is a highly effective rescue treatment and should be considered in patients who have had >2 recurrences, as the efficacy of antibiotics in these patients is ~30%. A randomized controlled trial of FMT revealed that it is effective (~81%) in treating multiple recurrent CDI 206 (FIG. 9) . FMT is best reserved for patients with multiple recurrences of CDI who have failed to respond to other treatment options. Importantly, FMT is a non-standardized procedure, and the long-term consequences of altering a patient's gut microbiota are unknown. Several national guidelines have, therefore, been developed to standardize FMT, including donor screening and selection [207] [208] [209] . Results from a preliminary study among patients with relapsing CDI revealed that administration of FMT using frozen encapsulated inoculum from unrelated donors also resulted in a good outcome 210 . It is likely that future research will define mixtures of selected micro organisms, designed according to the microorganisms' roles in the microbiota against CDI, as 'pharmacological' alternatives to FMT. For example, a mixture of 33 bacteria has been shown to be effective in two patients with CDI 211 , although the selection of the isolates was not based on microbiota studies. Rectal bacteriotherapy with a mixture of 12 bacteria from healthy donors resolved CDI and prevented recurrence within 30 days in 64% of the patients 212 . A combination of four bacterial species selected on the basis of strongest association with resistance to CDI, protected 
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. For moderate CDI, metronidazole is given orally, in severe cases intravenously. Hospitalization refers to admission as a result of CDI (not as a result of comorbidities; patients might already be hospitalized). Note that recurrence after clinical cure (resolution of symptoms) can be observed. Faecal microbiota transplant is an effective but non-standard form of treatment (shown by a dashed line). *Fidaxomicin is a treatment option if the risk of recurrence is high, but not for complicated CDI. mice from infection, most probably indirectly through an effect on bile acid metabolism 42 . As noted for FMT, long-term safety data on rectal bacteriotherapy will be needed, given the far-reaching effects of gut microbiota in health and disease.
Novel therapeutics
Several therapeutics targeting different stages of CDI are currently in clinical development (TABLE 1) . In brief, these consist of treatments to restore a complex microbiota (SER-109) 213 , to prevent off-target effects of antibiotic treatment on the intestinal microbiota (SYN-004), to neutralize C. difficile toxins (including monoclonal antibodies) 214 or to inhibit C. difficile proliferation (SMT19969, LFF571, surotomycin, cadazolid, PolyCAb and CRS3123).
Quality of life Economic burden of CDI
The burden of health-care-associated CDI can be expressed in terms of mortality, recurrence, (additional) length of hospital stay or economic cost [215] [216] [217] . Economic analyses of health-care-associated CDI have shown that direct health-care cost, and costs due to increased length of stay, were the main cost drivers. An integrative review showed a wide variation in the difference in length of stay between people with and those without CDI (2.8-16.1 days), which was attributed to differences in design and data collection 218 . Overall, people with CDI stay longer in hospital than people without CDI despite this variation.
A systematic review of the effects of CDI in Europe showed that the median length of stay for patients with CDI was in the range of 8-27 days, with an additional length of stay (due to CDI) of between 2.8 days and 18 days 217 . The incremental per-case cost of CDI in this study was UK£4,577 in Ireland and £8,843 in Germany, after standardization to 2010 prices 217 . Others have estimated the incremental per-case cost of CDI, after standardization to 2008 prices, to be US$2,871-90,644 (REFS 216,219) (FIG. 10) . A recent meta-analysis identified a total of 45 studies (mostly from North America) that measured the economic impact of CDI. For hospitalized patients, attributable mean CDI costs ranged from $8,911 to $30,049. However, the authors noted that costing methods were heterogeneous, making inter-study and setting comparisons difficult. Standardization of such measurements would be helpful, although differences between health-care systems remain a barrier when comparing financial costs 220 . The total direct cost of CDI to the European Union in 2006 was estimated at €3 billion per year 6 . Assuming a 3% annual inflation rate, this approximates to >€4 billion in 2015. Estimates for the economic burden of CDI in the United States and Canada are in excess of US$1 billion 221 and CAN$280 million 222 , respectively. These figures do not include the indirect socioeconomic costs (see below). Only for Canada does the estimate include a parameter for community-associated CDI in addition to health-care-associated CDI 222 ; so, the total burden in the United States and European Union probably exceeds the numbers given above.
Patient-reported quality of life
The stark mortality rates associated with CDI emphasize the serious consequences of this disease. Furthermore, given that CDI is characterized by diarrhoea, relatively frequent symptomatic recurrences and often altered bowel habit for possibly weeks or months following cessation of acute symptoms, it is perhaps not surprising that patients regularly report that this disease is one of the worst that they have experienced 223 . As patients are typically older and have comorbidities, the additional burden of CDI can affect both their dignity and ability to cope. Despite these well-recognized effects of CDI, very few data are available to formally measure how the disease affects an individual's health status, functionality and quality of life. Two recent studies have begun to explore these under-reported issues.
A prospective study of 66 outpatients with CDI used the RAND Short-Form 36 (SF-36) Health Survey and concluded that CDI significantly decreased overall quality of life but that a more specific healthrelated questionnaire is needed. The Patient-Reported Outcome Measurement Information System (PROMIS; http://www.nihpromis.org) is a large, US National Institutes of Health-funded database of questions to measure patient-reported health status for physical, mental and social well-being. PROMIS has recently been explored in a prospective, observational, multicentre study as a potential way to evaluate self-reported health status in patients with CDI 224 . Patients (n = 95) with active CDI (58%) or who were hospitalized (42%) had worse scores with regard to bowel function, nausea and abdominal pain compared with controls (P < 0.001). Those with recurrent CDI had worse anxiety scores than any other group (patients with first occurrence of CDI and controls; P < 0.001). The authors concluded that the 18 patient-reported health status questions were discriminatory for active CDI and primary versus recurrent CDI. These questions might be suitable for measuring short-term and long-term differences in patient-reported health status in people with CDI. CDI can also have long-lasting effects on families, but there is no systematic evaluation of these effects. More work is needed to optimize these measurements and to determine which interventions are associated with the best improvements in outcomes for both patients and relatives.
Outlook
Outstanding research questions
Substantial progress has been made in our understanding of C. difficile physiology and pathogenesis. Studies have provided insight into the workings of the pathogen and highlighted aspects of its biology that differ from the situation in other studied bacteria. For instance, the order, activation and function of sporulation sigma factors of C. difficile deviate from what is known for the best-studied Gram-positive spore former, Bacillus subtilis 225 . Perhaps this difference should not come as a surprise, as the last common ancestor of bacilli and clostridia dates back ~2.7 billion years, only shortly after the divergence of Gram-positive and Gram-negative bacteria (3.2 billion years ago) 226 . It is conceivable that more detailed investigations of the molecular biology of clostridia in general, and C. difficile in particular, will reveal unexpected features.
Laboratory investigations under controlled conditions have clearly demonstrated that the production of enterotoxins is regulated in a complex manner and integrates signals from both bacterial metabolism and the culture conditions 99 . It is uncertain, however, whether this process reflects infection within the host. Mutants that are used to assess these effects in the laboratory might display reduced virulence as a result of reduced fitness. Although the role of enterotoxins in disease is established, it remains unknown how toxin production is triggered in vivo, and how or when the toxins are secreted into the gastrointestinal tract. Similarly, it is unknown what triggers sporulation during infection. Both toxins (production and activity) and spores have been implicated in epidemicity 82, 122, 227 . However, strong evidence supporting this link is lacking and the ability of C. difficile to cause epidemics is likely to be a multifactorial process that involves a delicate balance of factors that affect virulence and transmissibility 74, 75 . It should be noted that increased virulence might not correlate with transmissibility, which might be favoured when hosts remain relatively healthy 75 . In faecal microbiota transplant (FMT), faecal material from a healthy donor is collected. The material is processed (blending, filtration) into pills or a solution. As part of this process, a check for the presence of pathogenic and multidrug-resistant organisms is performed. The processed material can be stored before (one-off) administration by nasoduodenal infusion, colonoscopic infusion or rectal enema for solution formulations or orally for pill formulations. Antibiotic treatment generally precedes the administration of the FMT to reduce Clostridium difficile levels. Alongside FMT, efforts are ongoing to standardize bacteriotherapy. On the basis of microbiome and metabolome analyses, signatures of resistance to colonization by C. difficile are identified. After collecting faecal material from healthy donors, species identified in these microbiome signatures or believed to be responsible for the metabolomic signature are cultured. Defined mixtures of these strains are tested for safety and ability to confer colonization resistance in preclinical trials and subsequently validated in clinical studies. Coloured bars indicate diversity of the microbiota, which is severely reduced in the patient with C. difficile infection (CDI) compared with the healthy subject.
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Process
Epidemic types of C. difficile have received considerable attention as a result of their higher mortality and morbidity in comparison to other, non-epidemic, types 7, 8, 12, 18, 82 . Often, enhanced infection control measures are taken when transmission of epidemic C. difficile types is detected, which has probably contributed to the decline of PCR ribotype 027 in different countries in 2014 (REF. 32 ). But is the increased vigilance towards these strains warranted? First, epidemiological analyses ignore the fact that not all strains of the same PCR ribotype exhibit the same characteristics, as has been demonstrated for sporulation 228 . Second, other PCR ribotypes can also cause outbreaks of CDI 20, 21, 229 . Third, with the advent of sequence-based typing methods, it is becoming clear that strains with different PCR ribotypes can be highly related 98, 230 . For instance, strains of PCR ribotypes 244 and 176, which are related to PCR ribotype 027, can cause outbreaks of severe CDI 22, 23 . PCR ribotype 244 seems to be primarily implicated in community-associated CDI, indicating that highly related strains might emerge as epidemic types in different settings 231 . Finally, new types could emerge. Thus, care should be taken to not generate an unjustified bias towards certain strains in epidemiological vigilance.
Colonization and pathogenesis
What determines whether C. difficile successfully establishes an infection is an important question. The host microbiota and its associated metabolites greatly influence the ability of C. difficile spores to germinate and colonize the gut 39, 43 . However, niche-specific competition 232 or collaboration (for instance, in a multispecies biofilm 56, 58 ) might also contribute. Most of the metagenomic studies have focused on bacterial species, whereas the contribution of fungal species and viruses (bacteriophages) is poorly explored. Notably, population groups with relatively unstable microbiomes (that is, infants 185 and the elderly 233 ) are most commonly colonized by C. difficile. Other host factors might also play a part. Failure to mount a protective immune response is associated with disease progression; patients with an adequate response could either eliminate the infection or become asympto matic carriers 14 . Host-dependent expression levels of toxin or colonization factor receptors could also be an important determinant for disease develop ment. It has been postulated that infants remain asymptomatic in the presence of high levels of toxins due to the absence of receptors in their stilldeveloping gastrointestinal tract; however, there is no evidence yet to support this hypothesis. Detailed studies of the interaction of C. difficile with the host are necessary to delineate the contribution of host factors to colonization and pathogenesis.
Clinical needs
Although antimicrobial resistance of C. difficile is not a major issue in the clinic, novel narrow-spectrum therapeutics are needed. The primary reason is that current (broad-spectrum) antibiotics with activity against C. difficile, such as metronidazole and vancomycin, can concurrently predispose patients to CDI (and possibly recurrent CDI) owing to their effects on other members of the microbiota 234 . Furthermore, some anti biotics are not cost-effective as first-line treatment options. It is possible that specific prophylactic elimination of C. difficile in high-risk groups could reduce the risk of CDI without altering the host microbiota. It is of interest that bacteriocins and viruses (bacteriophages) seem to be able to target C. difficile specifically 232, 235, 236 . FMT is an excellent potential alternative to antibiotic therapy 206 , but long-term safety, public acceptance and relative lack of standardized donor material are limiting broad application. Steps have been taken to generate standardized formulations of FMT or bacteria 42, 149, 211, 212 . However, it remains to be established whether a single species of bacteria or mixtures of different bacteria are effective for all (or most) patients. It is likely that bacterial or metabolic signatures need to be identified that confer broad protection or activity against CDI (FIG. 9) .
Antivirulence strategies 237 might become valu able additions or alternatives to the current therapeutic spectrum. Neutralizing antitoxin antibodies have shown clinical promise 214, 238 (TABLE 1) , and toxin activity has also been targeted using small molecules 128, 129 . Interference with quorum sensing or colonization factors has been underexplored so far, although it is clear that these factors can also be targeted by antibodies 239, 240 . Small-molecule inhibition of extracellular protein processing or function could prove a viable strategy to reduce colonization or transmission of CDI.
A final issue is the clinical need for accurate prediction models 155 . Accurate risk assessment tools that can be applied in real time would be beneficial to target diagnostic methods and for optimized treatment of those at risk of severe or complicated CDI, or recurrence [241] [242] [243] [244] . Although several tools have been developed, there is considerable room for simplification and improvements in predictive values to make these tools applicable at the bedside.
The burden of CDI Current conservative estimates of the economic burden of CDI are based on estimates of incidence and an incremental -per (hospitalized) patient -cost. These estimates fail to take into account the changes in demographics that are projected over the coming years. Age is a risk factor for CDI, although it is unclear whether this is an independent factor or caused by underlying confounders (such as immune senescence, comorbidities, need to stay at long-term care facilities and additional required health care). The European Union has projected that the demographic old-age dependency ratio (the ratio of those aged >65 years old to those aged 15-64 years) will increase from 27.8 to 50.1% between 2013 and 2060 (REF. 245 ). Similarly, US-based population projections foresee an increase in the percentage of people aged >65 years of 13.7-20.9% between 2012 and 2050 (REF. 246 ). On the basis of these projections, the impact of CDI is expected to become considerable in coming years.
Epidemiological evidence suggests that an increasing number of CDI cases is linked to populations that are generally considered to be at low risk for CDI. These community-associated infections generally affect a different demographic (younger patients) who have frequently not been exposed to antibiotics. Further studies are required to determine risk factors for community-associated CDI. As many cases of community-acquired CDI go undetected 24, 27, 29 , more studies are required to determine its contribution to the total burden of CDI at national and international levels.
Finally, C. difficile is increasingly recognized in veter inary medicine, with highly variable disease entities in different species of animals. No information is available to date on the economic burden of CDI in the food (animal) production industry. 
